Skip to content
media1

Group News

Message to all Aspen employees from Gus Attridge

Apr 6, 2020
Read More >>

Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Mar 17, 2020

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced that the Group is actively focused on employees carrying out best practices in respect of the prevention and containment of COVID-19 while ensuring continued supply of medicines to patients. Stephen Saad, Aspen Group Chief Executive said, “As…

Read More >>

Aspen increases revenue and progresses on medium-term priorities

Mar 5, 2020

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 31 December 2019. GROUP PERFORMANCE (CONTINUING OPERATIONS) Aspen increased revenue by 3% to R18,4 billion for the six months ended 31 December 2019. Commercial Pharma increased 2% to…

Read More >>

OPINION: Let’s pause for a moment to reflect on SA’s ARV success

Dec 4, 2019

By Stavros Nicolau, published in Independent Media’s Business Report JOHANNESBURG – Last week’s launch by Minister of Health Zweli Mkhize of a new ARV triple drug regimen in the Ugu district in KwaZulu-Natal and the commemoration of World Aids Day allows us as a country to reflect on how successfully we’ve managed what is arguably…

Read More >>

Aspen divests of its Japanese operations for up to R6.5 billion

Nov 11, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty and branded pharmaceutical company, is pleased to announced that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has concluded an agreement to divest of Aspen’s Japanese operations and related intellectual property to Sandoz, a Novartis Division, for a cash consideration of…

Read More >>

Aspen generates strong second half cash flows, reducing borrowings

Sep 11, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2019. Stephen Saad, Aspen Group Chief Executive said, “Despite the challenging environment, we have achieved most of our short-term goals, including the completion of the disposal…

Read More >>

Aspen hosts more than 120 Mandela Day projects in 40 countries

Jul 17, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is again reaching out to less fortunate citizens through its Mandela Day projects being hosted on 6 continents. Stephen Saad, Aspen Group Chief Executive Stephen Saad, Aspen Group Chief Executive said, “This is the ninth year that we will…

Read More >>

Aspen opens anaesthetic building as part of €100 million investment at its French-based site

Jun 18, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has expanded its specialist sterile production site at Notre Dame de Bondeville in France to augment the Group’s global manufacturing facilities. Stephen Saad, Aspen Group Chief Executive said, “The new state-of-the-art facility for anaesthetics, together with the new high-speed…

Read More >>

Department of Health and PHEF celebrate investment in human resources

May 1, 2019

The South African National Department of Health (NDoH) and the Public Health Enhancement Fund (PHEF) celebrated their investment in human resources for health in honour of the late Prof Bongani Mayosi on 30 April 2019. The public and private healthcare sector leaders and professionals converged in honour of post-graduate and medical doctors from various healthcare…

Read More >>

Aspen approved for secondary listing on A2X

Mar 25, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has been approved for a secondary listing on A2X Markets with effect from 1 April 2019. Stephen Saad, Aspen Group Chief Executive said, “We continually strive to identify ways to increase value for our shareholders and the complementary A2X…

Read More >>
Scroll To Top